| Document |
Document Title |
|
WO/2024/056099A1 |
Provided is use of a compound of formula I, formula I', or formula I", and a tautomer, a stereoisomer, or a pharmaceutically acceptable salt thereof as an METTL3 inhibitor. The compound can be used for treating a condition and a disease ...
|
|
WO/2024/056079A1 |
The present invention relates to a polymorphic form of a nepicastat acid addition salt, a preparation method therefor and a use thereof. The acid addition salt is selected from hydrochloride, sulfate, phosphate, mesylate, benzenesulfonat...
|
|
WO/2024/057351A1 |
Nausea and vomiting are unpleasant events induced by multiple triggers. Among them, drugs frequently prompt nnaauusseeaa and vomiting. Antitumor chemotherapeutics are among the most emetic drugs and often cause the so- called chemotherap...
|
|
WO/2024/059559A1 |
The invention provides isothiazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or co...
|
|
WO/2024/058722A1 |
The present disclosure relates to a method of treating neuroinflammation. The disclosure, in one aspect, provides for the administration of an effective amount of at least the four herbal components Polygalae (thin leaf milkwort), Astrag...
|
|
WO/2024/056016A1 |
The present invention relates to a free base crystal form of a polycyclic compound of a nitrogen-containing heterocycle, and a preparation method therefor. Specifically, the present invention provides a free base crystal form of a compou...
|
|
WO/2024/059052A1 |
A composition, comprising: two or more oligosaccharides selected from th egroup consisting of 2-fucosyllactose (2FL), 3-fucosyllactose (3FL), and 3-sialyllactose (3SL) is disclosed.
|
|
WO/2024/057782A1 |
This agent for improving brain function comprises at least any of compounds represented by structural formulae (1)-(3).
|
|
WO/2024/058196A1 |
The present invention aims to provide a novel agent for treating Alzheimer's disease, a method for treating Alzheimer's disease, a method for screening for a candidate substance for a therapeutic drug for Alzheimer's disease, and the lik...
|
|
WO/2024/056775A1 |
The present invention is directed to compounds of formula IIa. These compounds are considered useful for the treatment of diseases associated with leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease. Furthermore, the inventi...
|
|
WO/2024/059331A1 |
The present application discloses an erythritol analog of phenylbutyrate, and compositions including same. Also disclosed are methods of using the erythritol analog of phenylbutrate.
|
|
WO/2024/059659A1 |
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, Y1, Y2, X1, X2, X3, Q1, and Ra are as defined elsewhere herein. Also provid...
|
|
WO/2024/057039A1 |
The present invention relates to a method of treatment wherein a composition comprising a cannabinoid and an amphiphilic carbohydrate compound such as GCPQ is administered intranasally. The method of treatment is particularly suitable fo...
|
|
WO/2024/056678A1 |
The present invention relates to compounds according to formula (I), which are prodrugs of the psychoactive compound phenethylamine or its derivatives. The prodrugs provided herein exhibit improved pharmacokinetic properties during uptak...
|
|
WO/2024/055118A1 |
The present disclosure relates to a use of minor cannabinoids in the management or treatment of a seizure disorder in a patient. Minor cannabinoids include cannabichromene (CBC), cannabichromenic acid (CBCA), cannabigerol (CBG), cannabig...
|
|
WO/2024/056902A2 |
The disclosure features compositions and methods for the treatment of disorders associated with expression of wild-type or mutant Ataxin-2 (ATXN2) RNA transcripts, including disorders characterized by genes containing aberrantly expanded...
|
|
WO/2024/059608A1 |
Provided herein is a deuterated compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R15a, R15b, R16a, R16b, R17, R18, R19, R21a,...
|
|
WO/2024/055457A1 |
Provided is the use of a JWA polypeptide in the preparation of an anti-Parkinson's disease drug. The amino acid sequence of the polypeptide is as shown in I or II: I: FPG SDRF-Z; II: X-FPGSDRF-Z, wherein amino acid S is subjected to phos...
|
|
WO/2024/055758A1 |
The present invention relates to the technical field of biological medicines. Disclosed are a cyclic dinucleotide metal compound, and a preparation method therefor and a use thereof. The structural formula of the compound is [M(cyclic di...
|
|
WO/2024/058077A1 |
Provided is a technology that can promote neuronal migration. This pharmaceutical composition for treating brain disease includes a neuraminidase inhibiting substance. This neuronal migration promoter includes a neuraminidase inhibiting ...
|
|
WO/2024/059249A1 |
The present disclosure provides compounds of Formula I: (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described he...
|
|
WO/2024/058552A1 |
The present invention relates to a pharmaceutical composition for preventing or treating degenerative brain diseases, comprising cannabinoids as an active ingredient, and uses thereof. The present invention has confirmed that treatment w...
|
|
WO/2024/056995A1 |
The invention provides a combination of a PI3K/AKT/mTOR pathway inhibiting compound and a tanshinone or a derivative, an isomer or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/059739A1 |
The present disclosure provides anti-tau antibodies and vectorization thereof (e.g., into AAV particles). Also provided are methods of using anti-tau antibodies and/or AAV particles for prevention, treatment, and/or diagnosis of neurolog...
|
|
WO/2024/059661A1 |
Provided herein are compounds of formula (I) or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, R1, R2, R3, R4, Y1, Y2, X1, X2, L, and Q1 are as defined elsewhere herein. A...
|
|
WO/2024/059200A1 |
Compounds having activity as inhibitors of NEK7 are provided. The compounds have Structure (I): (I) or a stereoisomer, tautomer, or salt thereof, wherein A, W, X, Y, Z, R1, and R2 are as defined herein. Methods associated with preparatio...
|
|
WO/2024/059717A1 |
Methods for treating a neuropsychiatric disorder by administering an iboga alkaloid and a cardioprotective agent in conjunction with analysis of brain image data is described. Also described are methods to improve brain health and to slo...
|
|
WO/2024/059781A1 |
Described are 6-aryl isoindolin-1-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating ...
|
|
WO/2024/059845A1 |
A method of inhibiting propagation of protein misfolding associated with a neurological disease, is carried out by contacting an environment populated with a propagating amyloid conformation of a protein (prion) associated with a neurolo...
|
|
WO/2024/056498A1 |
The present invention relates to a compound having general Formula (I), (I), (e.g., oxindole alkaloid or its derivatives; (e.g., rotundifoline and rhynchophylline (compounds 1 and 2) or their derivatives or analogues thereof) for use as ...
|
|
WO/2024/059713A2 |
Compositions comprising an iboga alkaloid and a cardioprotective agent are provided. Use of the compositions in treating neuropsychiatric disorders are described, where the cardioprotective agent is administered before, during and/or aft...
|
|
WO/2024/058276A1 |
Provided is an agent for improving the composite memory of a normal person, which contains uridylic acid as an active ingredient.
|
|
WO/2024/059756A1 |
Heart failure WITH Preserved Ejection Fraction (HFpEF) effects approximately three million people in the United States.
|
|
WO/2024/058812A1 |
The embodiments of the present invention relate to a stable liquid vigabatrin pharmaceutical compositions in the liquid form of a solution. Particularly, the stable vigabatrin liquid pharmaceutical composition is manufactured as a ready-...
|
|
WO/2024/059688A2 |
The present disclosure provides compositions, methods, kits and uses for regulating blood-Central Nervous System (blood-CNS) barrier permeability (e.g., increasing or decreasing blood-CNS barrier permeability) by regulating signaling bet...
|
|
WO/2024/059665A1 |
Provided herein are compounds of formula (I): (G1-Z1)-L-(G2-Z2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G1, G2, Z1, Z2, and L, are as defined elsewhere herein. Also p...
|
|
WO/2024/059056A1 |
This disclosure relates to methods of treating or preventing traumatic brain injury (TBI) or related conditions comprising administering an effective amount of poly [4-styrenesulfonic acid-co-maleic acid] (PSCMA) or alternative anionic p...
|
|
WO/2024/055804A1 |
Provided are a nanocomposite for targeted degradation of a pathogenic protein, a preparation method therefor, and use thereof, which pertain to the technical field of nanobiological drugs. The nanocomposite for targeted degradation of th...
|
|
WO/2024/056154A1 |
The invention relates to the use of IL-2 in treating autism spectrum disorder (ASD) in a subject, as well as in preventing ASD in children, by administering the IL-2 to a child at risk of ASD or to a pregnant mother at risk of having a c...
|
|
WO/2024/059524A1 |
The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condi...
|
|
WO/2024/057339A1 |
The present disclosure provides methods for treating a cognitive impairment due to Itch dysregulation in a patient by administering a viral vector comprising a polynucleotide sequence encoding an Itch mutant to the patient. The Itch muta...
|
|
WO/2024/057898A1 |
[Problem] To provide an antibacterial agent that is highly safe and inhibits, at a low concentration, the growth of oral bacteria such as Porphyromonas gingivalis causative of various diseases. [Solution] By using honeydew honey as an ac...
|
|
WO/2024/057193A1 |
The present invention relates to crystalline forms of psilocin (4-hydroxy-N,N-dimethyltryptamine) salts or cocrystals, as well as compositions, methods of preparation and methods of their use. The present invention also relates to said c...
|
|
WO/2024/055810A1 |
Use of 6-phosphogluconic acid and a derivative thereof in preparing a medicament for preventing or treating glycometabolism disorder diseases. The 6-phosphogluconic acid and the derivative thereof are a type of cell glycometabolism regul...
|
|
WO/2024/051843A1 |
A pharmaceutical composition for preventing and treating convalescent stage facial nerve paralysis and a use thereof. The pharmaceutical composition contains any one among or a combination of mannitol, sodium aescinate, acyclovir, valacy...
|
|
WO/2024/054919A1 |
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds can be useful in the treatment of conditions such as depression and related disorders. Orally available formulations and other ph...
|
|
WO/2024/052895A1 |
This invention provides in some aspects, combinations, compositions and kits comprising a psychedelic drug and an NMD A receptor agonist and applications and uses of same for treating, reducing the incidence of, reducing the severity of ...
|
|
WO/2024/052553A1 |
A combination of N-acetyl-L-cysteine, selenium in the form of selenomethionine and melatonin, and a medical product or pharmaceutical composition comprising such combination, useful for the treatment of a variety of diseases and conditio...
|
|
WO/2024/051631A1 |
Disclosed are a macrocyclic imidazo[1,2-b]pyridazine compound represented by formula (I) or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer, a tautomer thereof or an isomer mixture thereof, or a...
|
|
WO/2024/051847A1 |
The present invention relates to a pharmaceutical composition for preventing and treating facial nerve micro-entrapment syndrome and a use thereof in the treatment of facial nerve micro-entrapment syndrome. The use comprises joint utiliz...
|
